Evidence map›Paper›PMID 42199484›Full record

ArticleClinical interventions in aging2026

Bronchial Arterial Chemoembolization with versus without Anlotinib in Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Case-Control Study.

Linqiang Lai, Tongguo Si, Hongxiang Yao, Shaolin Gong, Xuhua Duan, Zhi-Cheng Jin, Dengke Zhang, Jiansong Ji, Jianfei Tu

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical interventions in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Linqiang Lai *Department of Thoracic Center, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, 323000, People's Republic of China.
Tongguo Si *Interventional Radiology Department, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
Hongxiang YaoInterventional Radiology Department, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People's Republic of China.
Shaolin GongInterventional Radiology Department, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310000, People's Republic of China.
Xuhua DuanInterventional Radiology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, People's Republic of China.
Zhi-Cheng JinCenter of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, 210009, People's Republic of China.
Dengke ZhangDepartment of Thoracic Center, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, 323000, People's Republic of China.
Jiansong JiDepartment of Thoracic Center, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, 323000, People's Republic of China.ORCID 0000-0001-6975-620X
Jianfei TuDepartment of Thoracic Center, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, 323000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To compare bronchial arterial chemoembolization (BACE) plus anlotinib versus BACE alone for advanced non-small cell lung cancer (NSCLC) in the elderly. Patients and Methods: We screened all elderly patients (≥75 years of age) receiving BACE (75 mg/m Results: The final analysis included 95 patients: 33 and 62 in the BACE/anlotinib and BACE groups, respectively. The median lines of previous anti-tumor therapy was 1 (range, 1-3) and 1 (range, 1-3) in the BACE/anlotinib and BACE groups, respectively. The median OS was 39 months and 18.9 months in the BACE/anlotinib and BACE groups, respectively (hazard ratio 0.12, 95% confidence interval 0.06-0.24; Conclusion: In comparison to BACE, BACE plus anlotinib was associated with improved OS in elderly patients with NSCLC.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungChemoembolization, TherapeuticIndolesLung NeoplasmsQuinolinesAgedAged, 80 and overBronchial ArteriesCase-Control StudiesCisplatinFemaleGemcitabineHumansMaleRetrospective StudiesanlotinibAntineoplastic AgentsCisplatinGemcitabineIndolesQuinolinesanlotinibbronchial arterial chemoembolizationelderly populationnon-small cell lung cancer

Identifiers

PMID42199484
PMCPMC13199615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.